GlassScriptPhysician profile
Michelle G Archer
NPI 1598731556
$3,463.86
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,330 · 2020: $134.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $2,778.87 | 2019 | |
| Novo Nordisk INC | $200.23 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $105.55 | 2019-2020 | |
| Amgen INC. | $97.10 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $68.49 | 2019-2020 | |
| Lilly USA, LLC | $57.59 | 2019-2020 | |
| Glaxosmithkline, LLC. | $56.40 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $29.08 | 2019 | |
| Allergan, INC. | $15.40 | 2020 | |
| Pfizer INC. | $15.23 | 2019 | |
| Merck Sharp & Dohme LLC | $14.28 | 2019 | |
| Shire North American Group INC | $14.27 | 2019 | |
| Kaleo, INC. | $11.37 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michelle Archer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.